Posts by:

Laura Jackson

Supporting Vets with Post Mortem Histopathology

At VPG, we understand that post mortem submissions can be an essential part of veterinary diagnostics, helping to provide answers in difficult cases and contributing to wider clinical understanding. Our Histopathology team is here to support you with a straightforward submission process and accurate interpretation of findings.

When to Submit Tissues or Cadavers

In some circumstances, transporting a full cadaver to our laboratories is not practical. To support you, we provide a flexible approach:

  • Tissue submissions (PM1 – PMC 6+ tissues): for samples taken during a full or partial post mortem performed in practice.

  • Small cadaver submissions (HPMC): we can accept cadavers no greater than 10 cm in length (e.g. fish, mice or invertebrates) for necropsy on site at our Bristol laboratory. These must be fully submersed in formalin before submission.

Both tissue and cadaver submissions can be sent through the same service you already use for histopathology work.

What Information to Include

To ensure our pathologists can provide the most accurate and valuable interpretation, we ask that you include as much relevant information as possible on the submission form. This should cover:

  • A detailed clinical history, including presenting symptoms, observed lesions, and any treatment or medication given.

  • If euthanasia was performed, the method used.

  • Any recent changes in environment or housing.

  • Whether other animals are affected.

  • A short summary of the post mortem examination findings.

  • Images (ante-mortem or post-mortem), or a complete post mortem report with relevant laboratory or imaging results.

  • Clinical differential diagnoses you are considering.

  • Please also note if there is any suspicion of mycobacteriosis or other potentially zoonotic disease.

This level of detail allows our laboratory technicians and pathologists to incorporate clinical and post mortem data into their interpretation, strengthening the diagnostic outcome.

New Post Mortem Form

We have introduced a new post mortem submission form, now available to download from our website. This ensures that all essential details are recorded consistently and can be incorporated into your case report.

📄 [Download the new Post Mortem form here]

If you are unsure about how best to proceed with a submission, or how a set of samples will be priced, our Histopathology team is happy to advise.

📧 [email protected]
📞 0117 951 1283

Our anatomical pathologists and laboratory staff are here to support you every step of the way.

💡 Excellence. Everywhere.

By 0 Comments

Webinar: Could microRNAs transform the future of cardiac diagnosis?

VPG, in partnership with MI:RNA, is evaluating a cutting-edge microRNA-based diagnostic for veterinary cardiology.

In this session, you’ll hear from leading experts on how microRNAs could complement existing diagnostics such as NT-proBNP and Troponin I, and what this might mean for decision-making in practice.

What You’ll Learn 

  • Discover why microRNAs react early in cardiac disease
  • Understand how this testing could enable earlier detection and accurate staging in dogs and cats
  • Explore how microRNA diagnostics could integrate seamlessly into your workflow

Who Should Watch? 

  • Veterinary cardiologists 
  • Internal medicine specialists with a cardiology interest 
  • General practitioners managing cardiac cases 

Simply fill out the short form below to watch the recording of the presentation:


 

 

By 0 Comments

CASE STUDY: Pneumocystosis in a Dog

Clinical history:

A 7-year-old, male neutered, Cavalier King Charles Spaniel presented with a four-week history of progressively worsening tachypnoea, developing into dyspnoea. CT imaging under sedation revealed generalised ground glass appearance throughout the lung fields, deemed to be consistent with non-cardiogenic oedema. The dog was treated with trimethoprim-potentiated sulfonamides and oxygen supplementation, but deteriorated and sadly died from cardiopulmonary arrest. A post-mortem sample of lung was submitted to VPG for histopathology.

Histopathology:

The lung tissue was diffusely consolidated. The alveoli were lined by hyperplastic type II pneumocytes and the interstitium was fibrotic. Alveolar spaces were flooded with oedema, fibrin or surfactant-type material, and large numbers of inflammatory cells, mainly macrophages and neutrophils. There were accumulations of foamy eosinophilic material visible in some areas within the alveolar spaces. When Grocott-Gomori methenamine silver (GMS) stain was applied, the foamy eosinophilic material was shown to be composed of numerous 3-4 micron diameter fungal organisms. This appearance was diagnostic for Pneumocystis sp. infection (pneumocystosis).

 

 

Figure 1.

This low-power image (H&E) shows lung consolidation. Alveolar spaces are no longer filled with air (should show as clear space). The bronchioles are still visible containing clear space though.

 

 

Figure 2.

This high-power view (H&E) shows the alveoli infiltrated with inflammatory cells (arrow head), multifocally filled with foamy eosinophilic material (horizontal arrows), and lined by type II pneumocytes (vertical arrows).

 

 

Figure 3.

With GMS silver stain, in the areas of foamy material, there are numerous round organisms (arrow heads), typical of Pneumocystis sp. Note that most of the foamy material is non-staining, which corresponds to the trophozoites. The silver stain only stains the cyst walls.

 

Histological diagnosis:

Interstitial pneumonia with intra-alveolar Pneumocystis sp

 

More information on Pneumocystis:

Clinical cases of canine pneumocystosis are rare. The clinical history of gradual onset respiratory disease, usually longer than 4 weeks, is common. The other most common clinical signs are exercise intolerance, cough, and weight loss despite normal feed intake. It is thought that underlying immune impairment is required for the causative agent, Pneumocystis carinii, to cause clinical disease, and this may be inherited or induced by immunosuppressive therapy. The Cavalier King Charles Spaniel is a predisposed breed for this infection owing to a suspected underlying immune deficiency. There is a known common variable immunodeficiency inherited in the Miniature Dachshund, making this the other most commonly affected dog breed. Foals with severe combined immunodeficiency (SCID) are also predisposed. At 7 years of age, this spaniel was older than most affected dogs (median 1 yr).

 

Pneumocystis carinii is a yeast-like fungus that is highly adapted to infect type I pneumocytes that line the alveoli in health. The typical histological picture is the presence of foamy material filling alveoli. This material is composed of numerous fungal cysts and trophozoites. The individual organisms are difficult to appreciate without a special silver stain (GMS) and can be overlooked if they are present in low numbers and only standard H&E stain is used.

 

This patient unfortunately succumbed to pneumocystosis. Dogs can recover but early treatment is generally needed to achieve this. Obtaining an antemortem diagnosis can be problematic, but bronchio-alveolar lavage fluid cytology is an effective and noninvasive method.

 

 

Alex Civello DipACVP FRCPath MRCVS

Board Certified Anatomic Pathologist

 

References:

1. Weissenbacher-Lang C, Fuchs-Baumgartinger A, Guija-De-Arespacochaga A, Klang A, Weissenböck H, Künzel F. Pneumocystosis in dogs: meta-analysis of 43 published cases including clinical signs, diagnostic procedures, and treatment. J Vet Diagn Invest. 2018 Jan;30(1):26-35. doi: 10.1177/1040638717742429.

2. Lobetti R. Common variable immunodeficiency in miniature dachshunds affected with Pneumonocystis carinii pneumonia. J Vet Diagn Invest. 2000 Jan;12(1):39-45. doi: 10.1177/104063870001200107.

By 0 Comments

Smart Diagnostics Part 2: AI to Improve Prognostic Accuracy in Ki67 staining of Canine Cutaneous Mast Cell Tumours

Cutaneous mast cell tumours (MCTs) are amongst the most common malignant skin tumours in dogs. Their biological behaviour can be variable and as a consequence the prognosis can be unpredictable. Whilst well-established grading systems have been developed and are routinely used to assess these tumours, namely the ‘two-tier’ (Kiupel et al 20I0) and older ‘three-tier’ (Patnaik et al 1984) grading systems, these do not correctly predict clinical outcomes in all cases. A subset of MCTs, identified as low/intermediate grade examples (Figure 1) using these grading schemes, do not act as indicated by the histologic grading. This subset of tumours can display more aggressive behaviour, including recurrence, nodal metastasis (Figure 2) and distant metastasis, ultimately resulting in euthanasia or death of some of the affected patients.

 

 

Figure 1. Typical histological appearance of a Grade II/low grade mast cell tumour,  exhibiting well-differentiated mast cell amongst a fibrous stroma, with accompanying eosinophilic inflammation.

 

 

Figure 2. Image of a nodal metastasis of a well-differentiated MCT. Neoplastic mast cells are seen to fill sinuses and efface the nodal architecture.

 

Multiple additional prognostic markers have been investigated to more precisely predict the prognosis of canine cutaneous MCTs. These tests, such as the Ki67 index, may help to identify those tumours likely to be in the aggressive subset of apparently histologically ‘low/intermediate’ grade MCTs.

 

What is the Ki67 index?

The Ki67 index is the most commonly requested prognostic marker for mast cell tumours and melanocytic neoplasms. It essentially measures the proportion of tumour cells that are actively dividing in a given snap shot of time. Elevated expression of Ki67 in mast cell tumours has been shown to be statistically associated with more aggressive tumour behaviour and poorer patient outcomes (Scase et al 2006; Maglennon et al 2008). However, formulation of this index typically requires manual counting of large numbers of individual mast cells under the microscope – a method that is inherently time-consuming. Other cells, including stromal cells and inflammatory cells, can also display positivity for this marker, adding to the complexity of interpretation of the test. At VPG, Ki67 stained slides are interpreted by anatomical pathologists experienced with the methodology and analysis. For inexperienced pathologists interpreting Ki67 stained sections, the test can be time consuming, and potentially susceptible to interobserver and intraobserver variability.

To address these limitations, a recent VPG study explored the use of artificial intelligence (AI)-assisted analysis to automate Ki67 cell counting in canine cutaneous MCTs. The goal was to increase efficiency, reduce interobserver and intraobserver variability, and ultimately support more accurate prognostication for clinical practice.

 

Development of the AI-Assisted Tool

The study utilised QuPath, a platform for digital pathology image analysis (Bankhead et al 2017). VPG pathologists trained a machine learning algorithm to identify and distinguish between Ki67-positive and Ki67-negative mast cells, as well as other neighbouring cells including inflammatory leucocytes, which may complicate the interpretation of the immunohistochemical staining (Figure 3).

Training was conducted using a dataset of 244 representative MCT images, allowing the machine to learn the relevant digital and microscopic features of positive and negative staining (this could include, for example, staining intensity, ‘roundness’ of the cells and other colour/shape parameters). To evaluate its performance, the trained AI system was tested on a separate set of 77 images, which were also reviewed manually by three board-certified veterinary histopathologists. This allowed for direct comparison between ‘machine’ and human in terms of accuracy and reproducibility.

 

 

Figure 3. Example of a Ki67-stained mast cell tumour (left). Dark brown round cells are considered to be positive mast cells in this image. A machine-interpreted image (right) highlights positive mast cells (red outline) and negative mast cells (blue outline). Other cells include stromal cells and eosinophils.

 

Key Findings

The AI-assisted method demonstrates good levels of accuracy, closely matching the results obtained by manual cell counting. Importantly, the automated system significantly reduces the time required to complete the analysis. It also allows for greater consistency across samples, helping to minimise interobserver variability. Remarkably, the time required to complete an image analysis is now less than 1 second, rather than the average time of a ‘manual count’, which is often several minutes.

These findings demonstrate that AI can be a practical advancement in the diagnostic workflow of veterinary pathology providers, particularly for specific tasks that are labour-intensive and potentially subject to interobserver and intraobserver variation. While AI does not aim to replace the expertise of a trained pathologist, it can serve as a valuable aid, particularly in high-throughput and laborious settings, or when standardisation is a priority. Incorporating this AI tool into diagnostic pathology offers benefits for both pathologists and clinicians; More efficient and reproducible Ki67 scoring allows for improved prognostic assessments.

 

Conclusion

The study aimed to validate the use of AI as a tool to assist with Ki67 cell counting in canine cutaneous mast cell tumours. Whilst traditional manual cell counting to attain a Ki67-index provides clinically useful prognostic information, AI-assisted counts enhance the process with more rapid and reproducible counts, reducing the physical ‘burden’ of a manual cell count. Whilst offering significant improvements in efficiency, all AI-assisted counts are verified carefully by a board-certified pathologist to ensure their accuracy.

 

References

Bankhead, P., Loughrey, M.B., Fernández, J.A., Dombrowski, Y., McArt, D.G., Dunne, P.D., McQuaid, S., Gray, R.T., Murray, L.J., Coleman, H.G. and James, J.A., 2017. QuPath: Open source software for digital pathology image analysis. Scientific Reports, 7(1), pp.1-7.

Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior. Veterinary Pathology. 2010;48(1):147-155.

Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984 Sep;21(5):469-74.

Maglennon GA, Murphy S, Adams V, Miller J, Smith K, Blunden A, Scase TJ. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Vet Comp Oncol. 2008 Dec;6(4):268-74. doi: 10.1111/j.1476-5829.2008.00168.x. PMID: 19178685.

Scase TJ, Edwards D, Miller J, Henley W, Smith K, Blunden A, Murphy S. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med. 2006 Jan-Feb;20(1):151-8. doi: 10.1892/0891-6640(2006)20[151:cmctco]2.0.co;2. PMID: 16496935.

By 0 Comments

How Targeted Microbiome Support Is Transforming Dog Health

Introduction 

Retesting is a vital part of how long-term gut health is supported through the BIOME9 supplement plan. Just like in human medicine, adjusting and optimising based on results is key to sustainable change. With over 100 individual retests now completed, BIOME9 has gathered robust evidence showing how precision microbiome support, guided by data and tailored supplements, can lead to measurable, wide-ranging improvements in dogs.

The Power of Retesting and Adjustment

Microbiome modulation isn’t a one-off fix. It’s a journey. BIOME9 recommends retesting after dogs have been on the supplement plan for 8 to 12 weeks. This gives both practitioners and owners a clear window into what’s changing and where further support might be needed.

In 101 individual retests, 83% of dogs showed significant improvements across core gut health scores and functions. These changes were not only reflected in lab data but also matched the improvements reported by owners: better digestion, calmer behaviour, fewer symptoms, and increased vitality.

Microbial Community Shifts: Diversity, Stability, and Beneficial Bacteria

Across the retests, the average increase in microbial diversity was striking. Diversity more than doubled, with an average of 167 additional bacterial species detected post-supplementation. Balance and stability—two hallmarks of a resilient microbiome—also improved by 39% on average.

Additionally, 68% of dogs saw an increase in all twelve core commensal (beneficial) bacteria. The most notable increases were seen in Megamonas, Fusobacterium, and Faecalibacterium—species associated with healthy digestion, anti-inflammatory functions, and immune regulation. This shift suggests that targeted supplementation supports broad microbial health and helps re-establish key populations that may have been lost or suppressed.

 

Digestive Function: Precision Nutrition at Work

Improving digestive efficiency is one of the core aims of microbiome modulation. After completing the supplement plan and retesting, dogs showed an average 12% improvement in digestive function. These gains weren’t just about symptom relief—they reflected better nutrient absorption and energy extraction from food:

  • +6% protein digestion

  • +9% carbohydrate digestion

  • +11% fibre digestion

  • +13% lipid digestion

  • +20% increase in vitamin and mineral absorption

By optimising the existing diet rather than replacing it, the BIOME9 plan supports precision nutrition, helping each dog get more out of the food it already eats.

Beyond Digestion: Whole-Body Benefits

While gut health is the foundation, the benefits of a balanced microbiome extend across multiple systems. In 91% of retests, dogs showed improved health markers beyond digestion.

For example, breath odour (a common complaint) improved by 28%, reflecting internal metabolic improvements rather than superficial masking. Neurological health scores rose by 12%, supporting what broader data has shown: nearly one-third of dogs with gut issues also experience behavioural symptoms.

Perhaps most striking was the impact on immune-related functions. Retests showed:

  • +8% improvement in coat and skin health

  • +16% increase in immune and cardiovascular markers

  • +17% reduction in markers of gut inflammation

  • +27% improvement in joints and mobility

These findings reinforce the microbiome’s central role in systemic health and highlight the importance of personalised, science-based support.

What We’re Learning, and What’s Next

With over 100 retests and counting, the data speaks for itself. Personalised microbiome support doesn’t just shift numbers—it transforms health outcomes. As BIOME9’s database continues to grow, it’s providing even more confidence in this precision-based approach and expanding understanding of how to support different breeds, life stages, and health challenges.

By 0 Comments

How to Get the Most From Your Cytology Samples

Here at the VPG, we encounter dozens of new, interesting and occasionally confusing cytological cases from your patients every day – our interpretations are greatly improved when we work as a team with our clinicians to get the best out of our samples. With that in mind, here is some advice on some things to consider (and some things to avoid) when sending in cytological samples.

Labelling slides

We process hundreds of slides a day across our sites. Accurate labelling helps avoid any problems during processing and staining, as well as saving time and avoiding confusion when we examine them. Some advice:

  • Label the submitted slides with the patient’s name, surname, and brief description of the sample location.
  • Label each slide individually – unlabeled slides in labelled slide holders are very hard to identify once removed from the box (although, ideally, label the slide holders too).

We find that felt pen written on slides can fade in transit or erased during the staining process; ink pen occasionally will be too. Sticky labels can also be lost on transit or during processing. Pencil written on frosted glass is preferable and unlikely to be lost. Scratching details onto a slide with an engraving tool can also work, although it can be time consuming for the clinician and hard to read.

 

 

**Fig 1 – A well-labelled slide with pencil on frosted glass**

 

Labelling fluids

  • Label every sample tube with the patient’s name and site of the sample (especially important when multiple fluids are submitted, or fluid is submitted alongside blood). The date of sampling is also useful for fluid samples to help us assess deterioration since sampling.
  • Where possible, submit direct fresh in-house smears as well as fluid (although this is largely unhelpful for poorly cellular fluids such as CSF or respiratory samples).
  • When in-house smears are included with a specimen, clearly label whether the preparation was smeared directly from the sample (direct) or whether the sample was concentrated prior to preparing the smear (concentrated). This makes it much easier for the pathologist to assess the cellularity of the sample.

 

Submission form

We understand the many demands on your time in practice, but correctly filling in a submission form will lead to a quicker result and often a more relevant report. We have received submissions missing any (or all!) of the information discussed below, and in each case the reporting of the sample has been slower as a consequence.

Patient and practice details

Include all salient details of the patient with the submission form – this includes name, age, species, breed, date of sampling, sex and neutering status – as well as the submitting practice and the clinician involved. Where some details are ambiguous or have recently changed (for instance, a sample taken from a patient that was neutered at the same time as sampling) then it helps to briefly explain this in the history section.

History

A concise and relevant history is extremely important for submissions; cytology is a subjective discipline, and the context in which samples are taken and examined is important. Samples with no history at all are likely to lead to a more equivocal report or a phone call from the lab requesting more details, delaying the report. Similarly, including unedited clinical notes for patient’s last few weeks, months or years can lead to relevant details being missed when sandwiched between pages of clinical notes, flea treatment and wormer sales.

The most helpful details to include with a submission are as follows:

  • Precise location of sites sampled (see below for some notes on anatomy)
  • Reason for sampling (e.g. lesions found on imaging, persistent enlargement, history of neoplasia elsewhere)
  • Gross appearance (or appearance on imaging/features on palpation for internal masses) e.g. hairless, diffuse versus discrete mass, hyper/hypoechoic, colour, texture, attached versus mobile
  • Other potentially relevant clinical findings (e.g. marked hyperglobulinaemia, hypercalcaemia, masses elsewhere not sampled)
  • Details from previous history which may be relevant (e.g. previous mast cell tumour, currently on chemotherapy, bouts of pancreatitis, history of trauma in the sample location)

It can also be useful to include the differential diagnoses you are most suspicious of or ask any clinical questions that you are particularly interested in, which can help focus the pathologist on the details most relevant to your case (e.g. ‘Concerned for mast cell tumour’; ‘Is this swelling a lymph node?’; ‘Suspect hepatic nodular hyperplasia but want to rule out neoplasia’ etc.)

 

Anatomy

Medical terminology (as well as providing useful face-saving terms such as ‘idiopathic’ and ‘iatrogenic’) furnishes clinicians with detailed ways of describing the precise location of lesions. It is a shame to allow these elegant terms to go to waste by instead using ambiguous language which can lead to confusion and misinterpretation. Here are some terms that will often need clarification (many don’t need to be completely avoided, but further details to locate lesions more accurately will be helpful):

Neck – this may seem like a precise term, but it actually covers everywhere from the thoracic inlet to the submandibular region, and says nothing about whether a lesion is dorsal, ventral, or lateral. ‘Neck lump’ could represent anything from a thyroid carcinoma to a sarcoma involving the spinous processes of the cervical vertebrae.

Throat – again, this may seem like a precise location, but actual covers a wide anatomical area, and, in isolation, does not make it clear whether a lesion is present within the oropharynx, larynx or the subcutaneous or cutaneous tissues surrounding them.

Rump – another term which can refer to large areas of a patient, from the dorsal pelvis, pelvic limbs, tail base or anal mass.

Bum – another non-specific term, although this one makes my kids laugh so has slightly more merit.

Abdominal/thoracic – remember to include details of whether lesions are intraabdominal/thoracic, or extraabdominal/thoracic. ‘Abdominal mass’ is more ambiguous than it appears at first.

Cervical – frustratingly, despite me waxing lyrical above about the elegance of anatomical terms, ‘cervical’ can actually refer to two separate anatomical locations: the cervical spine, or the cervix (it comes from the Latin for ‘neck’ but is often applied to general narrowing of tissues). Regardless, remember to clarify which location you are referring to with submissions.

Subcutaneous versus cutaneous – these are precise terms (as are their synonyms dermal and subdermal) but are often misused, especially as it can be challenging to tell the difference in some diffuse or invasive lesions. Cutaneous masses are usually visible on the skin’s surface or are clearly palpable just underneath it – if the skin is lifted, then a cutaneous mass lifts as well. In contrast, ‘subcutaneous’ masses are present beneath the surface of the skin and are only visible when they deform the overlying skin. The skin is generally mobile over subcutaneous masses except for lesions which have invaded the cutaneous layer, and when the skin is lifted, a subcutaneous mass should remain in its original position.

For lesions where it is not entirely clear whether the mass is cutaneous or subcutaneous, record this difficulty in classifying on the submission form.

Side/Dorsum/Ventrum – ‘side’ leads a lot to the imagination, encompassing both forelimbs, the neck (a vague term in itself), the thoracic and abdominal wall and can even be applied to mammary glands. ‘Dorsum’ and ‘ventrum’ are similarly non-specific when used alone.

Foot – this is relatively specific, but more information to clarify if a lesion is on a digit, interdigital, on a pad or in the nail base is helpful as it may affect the interpretation.

 

Packaging

Even when the sample has been successfully taken, labelled, and a concise and relevant history has been included, mistakes in packaging can significantly affect the quality of specimens and the chance of diagnosis. Here are the most common pitfalls to avoid:

Do not pack cytology with histopathology – unfortunately, cytology specimens are very sensitive to formalin fumes; even limited exposure has a significant effect on the quality and preservation of samples. Cytology exposed to formalin has a washed-out appearance, with erythrocytes and many nucleated cells faded, ruptured and often stained an unpleasant greenish colour. This can ruin an otherwise diagnostic sample.

To avoid the risk of this, submit histopathology and cytology specimens separately.

 

 

**Fig 2 – Greenish discolouration of red blood cells due to formalin fumes**

 

Do not package wet slides – when slides are placed into slide holders before they are fully dry, the condensation results in ‘drying artefact’ – it leads to rupture of many cells and markedly reduces the quality of samples. The telltale sign of drying artefact is red cells reduced to spiky haemoglobin crystals and this can, again, ruin a perfectly good sample.

To avoid this, ensure that slides are completely dry before packaging. For some samples (such as synovial fluid preparations), using a hairdryer on the cool/gentle setting can help to speed up the drying process.

 

 

**Fig 3 – Haemoglobin crystal formation due to packaging slides while still wet**

 

Avoid submitting slides with coverslips– these need to be removed to allow us the stain the samples. Removing them is time-consuming, sometimes difficult, and sometimes damages the specimen.

Avoid prestaining slides all submitted slides – we love cytology, and so quite understand that once you have taken a sample, you are interested in having a look yourselves. As pathologists, however, we are creatures of habit and ritual (notably manifested in our complicated tea runs), and we are accustomed to our modified Wright’s stain. Although pre-staining will not ruin preparations, it alters the staining properties of the slides and can make certain conditions more challenging to identify (for example, mast cell granules may not stain well, and nuclear features can be accentuated on pre-stained slides). Pre-staining, as with many things in life (except cheese) is fine in moderation, but it is helpful to leave some cellular slides unstained for us.

 

Take home messages

  • Label individual slides as well as slide holders, ideally with pencil on frosted glass
  • A concise and relevant history will help speed up the process and improve chances of a diagnosis
  • Use precise anatomical terms (avoid ‘neck’, ‘throat’, ‘bum’)
  • Package cytological and histological specimens separately
  • Do not package slides when they are still wet
  • Avoid submitting slides with coverslips on

Download your free Cytology Submission Checklist
Ensure every sample is prepped perfectly – print and keep this handy reference in your practice.


 

By 0 Comments

Smart Diagnostics Part 1: The Integration of Artificial Intelligence in Veterinary Histopathology

Smart Diagnostics Part 1: The Integration of Artificial Intelligence in Veterinary Histopathology

Traditionally, histopathology involves the manual microscopic analysis of tissue mounted on glass slides. Now, the once ubiquitous laboratory microscope is being rapidly replaced by advanced scanning apparatus, which digitises slides for display on PC monitors. However, tissue analysis remains a highly skilled and time-consuming process, requiring years of veterinary and specialist training to achieve proficiency. In veterinary pathology, this training, undertaken by veterinary surgeons, ultimately leads to board certification (e.g., European College of Veterinary Pathologists, American College of Veterinary Pathologists, or Royal College of Pathologists).

The role of artificial intelligence (AI) in our workplaces and daily lives is a ‘hot topic’. AI is increasingly being utilised across various sectors and has the potential to revolutionise both veterinary and human pathology. However, to obtain meaningful data and outcomes, the current technology is heavily dependent on training by expert pathologists. As such, at least for the foreseeable future, AI is not likely to entirely replace pathologists, but has the potential to increase efficiency and consistency – this provides benefit to the sector by helping to close the gap between the increasing demand for pathologists and relatively small number of board-certified pathologists.

Currently, in the pathology speciality, AI is most widely used for image analysis – specifically, interpreting histological images. Using expert pathologist input, artificial neural networks can be trained to recognise specific patterns associated with particular disease processes. For example, well-differentiated adenocarcinomas infiltrating tissue often form repeated epithelial-lined tubular structures. AI can ‘learn’ these patterns and assist pathologists by identifying similar structures in other tissues, allowing for the rapid detection of carcinoma metastases, for example. Additionally, AI could supervise the generation of pathology reports based on key histological features or biochemical data derangements, streamlining diagnoses and suggesting the most likely diagnosis or differential diagnoses to the anatomical pathologists reviewing a case.

AI in Human Pathology

AI has been extensively employed as a diagnostic assistance tool in human pathology. Notable examples include:

  • Tumour Detection and Grading: AI improves breast and prostate cancer diagnostics by enhancing accuracy and consistency (Nassif et al., 2022; Goldenberg et al., 2019).
  • Prognostic Factor Identification: AI can analyse large datasets to predict patient outcomes, such as in human cancers (Torrente et al., 2022) and COVID-19 progression (Jiao et al., 2021).
  • Cell Classification and Counting: AI tools offer faster, more consistent classification and counting of cell types, such as immune cell densities in tumour micro-environments (Rakha et al., 2021).

A relatively recent review article involving medics/histopathologists at the University of Nottingham, UK (Rakha et al., 2021) has identified numerous current and future uses of AI in the field. In short, AI can aid with standardising diagnoses in patients, specifically by allowing diagnoses to be more consistent and reproducible, and with increased speed. This can include streamlining defined points within the histopathology workflow, such as automatically requesting special stains, prioritising certain cases, automatically identifying quality control (QC) issues etc.

AI in Veterinary Pathology

While AI has shown significant yet early promise in human pathology, its use in veterinary pathology remains limited and in its infancy. However, recent AI applications in veterinary and toxicological pathology include:

  • Liver Fibrosis Assessment: AI has successfully quantified hepatic fibrosis in preclinical mouse models with accuracy comparable to board-certified toxicological pathologists (Ramot et al., 2021), with the potential of reducing manual workloads.
  • Canine and Feline Lymphoma Diagnosis: AI models can predict chemotherapy responses and subtype lymphomas by nuclear sizing, improving diagnostic accuracy (Koo et al., 2021; Haghofer et al., 2023).
  • Feline Chronic Enteropathy: AI-based models can quantify lymphocytes in feline intestinal biopsies, increasing reproducibility (Wulcan et al., 2024).
  • Bovine Mastitis Detection: AI may assist in early mastitis diagnosis, benefiting dairy industry efficiency and animal welfare (Mitsunaga et al., 2024).

Note that these examples are still in the realms of research based applications and are not currently commercially available tests.

Challenges and Ethical Considerations

Despite its potential, AI integration in pathology does face several challenges. Specific points to carefully consider include:

  • Data Quality: AI training relies on vast datasets, potentially containing erroneous data (e.g. human error) that can impact model performance. Furthermore, a solid ‘ground truth’ is required – this is the information that the machine ‘learns’. If a group of pathologists cannot agree on diagnosis (i.e. the diagnosis is ambiguous), then AI cannot be expected to make an accurate diagnosis.
  • Decision Making: As highlighted in a recent article (Rakha et al., 2021), neural networks operate as “black boxes,” (i.e. a system coming to a conclusion without a clear explanation for how a decision was made) making it difficult to understand and reproduce their decision-making processes.
  • Ethical Concerns: Issues such as data ownership and privacy may need to be addressed before AI models, trained on such data, are widely adopted or integrated into workflows.
  • Validation Standards: AI tools must be rigorously validated to ensure performance matches that of board-certified histopathologists. Few standardised guidelines exist for this validation process (Ma et al., 2025).

Conclusion

AI has the potential to transform the pathology speciality by increasing diagnostic efficiency, increasing diagnostic accuracy and reducing the workload for pathologists. However, it is not yet to be considered a replacement for human expertise but rather a tool for diagnostic assistance. As AI continues to evolve, the use of careful validation, consideration of ethical implications, and use of high-quality training datasets will be essential for its successful integration into veterinary pathology.

AI is a rapidly developing field which has much to offer the field of veterinary pathology, and also the services that VPG may offer in the future. As we endeavour to be experts and challengers, AI has the potential to offer more precise, standardised, and efficient diagnostic reporting, leading to more rapid and accurate clinical diagnoses for your clients and their pets. Ultimately this should lead to improved patient care and outcomes.

At the VPG, we have recently introduced AI-assessment of the Ki67 index in canine cutaneous mast cell  tumours. This topic will be discussed in Part 2 of this blog.

 

References

Goldenberg, S., et al. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol 2019, 16, 391–403

Haghofer A., et al,. Histological classification of canine and feline lymphoma using a modular approach based on deep learning and advanced image processing. Sci Rep. 2023, 13, 19436

Jiao, Z., et al. Prognostication of patients with COVID-19 using artificial intelligence based on chest x-rays and clinical data: a retrospective study. The Lancet Digital Health, 3, e286 – e294

Koo J., et al. Predicting dynamic clinical outcomes of the chemotherapy for canine lymphoma patients using a machine learning model. Vet Sci. 2021, 8, 301

Ma, Y, et al. AI in Histopathology Explorer for comprehensive analysis of the evolving AI landscape in histopathology. npj Digit. Med. 2025, 8, 156

Mitsunaga TM, et al., Current trends in artificial intelligence and bovine mastitis research: a bibliometric review approach. Animal. 2024, 9, 14

Nassif, A., et al. Breast cancer detection using artificial intelligence techniques: A systematic literature review, Artif Intell Med, 2022, 127, 102276

Rakha, EA., et al. Current and future applications of artificial intelligence in pathology: a clinical perspective. J Clin path. 2021, 74, 409-414

Ramot Y., et al, Microscope-based automated quantification of liver fibrosis in mice using a deep learning algorithm. Toxicol Pathol. 2021, 49, 1126-1133

Torrente, M., et al. An artificial intelligence-based tool for data analysis and prognosis in cancer patients: results from the clarify study. Cancers 2022, 14, 4041

Wulcan JM., et al., Artificial intelligence-based quantification of lymphocytes in feline small intestinal biopsies. Vet Path. 2024, 62, 139-151

By 0 Comments

Speed, Accuracy, and Better Patient Care: Why Turn-Around Times Matter

In veterinary practice, time matters. Lives can change from a single diagnosis so whether the results are good or bad, rapid exchange of information is vital to maximising patient welfare and pet owner experience. That’s why at VPG, we believe turn-around time (TAT) is more than a metric. It’s a clinical asset.

Veterinary professionals across the UK are under growing pressure to diagnose faster, treat earlier, and manage cases more efficiently. In this environment, choosing a diagnostic lab with fast, reliable turn-around times is essential. Here’s why it matters, and how VPG is leading the way.

What Is Turn-Around Time, and Why Does It Matter?

Turn-around time (TAT) refers to the period between when a sample arrives at the lab to when the results are reported to the client. It’s the heartbeat of diagnostics and, for many practices, the number one reason for choosing a lab partner (as indicated in a recent VPG client survey).

A shorter TAT means:

  • Faster decision-making during the diagnostic process
  • Earlier initiation of treatment plans
  • Reduced stress for clients waiting on results

In short, speed supports better care, but only when it’s matched by accuracy and clinical relevance. That’s where VPG excels.

VPG’s Industry-Leading Turn-Around Times

At VPG, we’re proud to deliver some of the fastest vet results in the UK, without sacrificing quality or accuracy. Here’s what you can expect across our core services:

 

How Faster Turn-Around Helps You and Your Patients

Quick access to results can make the difference between appropriate intervention and the risk of further complications associated with delays. With same-day cytology reporting times, for example, you can move from sampling to action within a single clinical day thereby preserving continuity of care for patients and reducing anxiety for pet owners.

Beyond individual cases, reliable TATs help practices:

  • Reduce bottlenecks in the diagnostic workflow
  • Improve communication with pet owners
  • Enhance client satisfaction and retention
  • Manage caseloads with greater predictability

VPG’s partners enjoy total visibility of all outstanding results via the PATHPORT platform which provides real-time updates, detailed patient histories, and the ability to request additional tests on existing samples.

Diagnose with Pace, Precision, and Confidence

Your veterinary pathology partner should support you, not slow you down. That’s why VPG is committed to providing fast vet results, personalised service, and clinical accuracy you can trust. With us, you’re not just getting results, you’re getting a partner in better patient care.

Ready to experience diagnostics that keep pace with your practice? To request more information about our clinical capabilities, contact us via our form here.

By 0 Comments

Case Study: Feline Herpes Virus-Induced Dermatitis: Clinical and Histological Insights

Case Study: Feline Herpes Virus-Induced Dermatitis: Clinical and Histological Insights

A biopsy from an external nose lesion on a 13-year-old domestic longhair male neutered cat was submitted to our laboratory. Histopathology identified a severe ulcerative necrotising dermatitis with numerous intranuclear inclusion bodies. These histological changes, in combination with the anatomical location are consistent with a herpesvirus infection.

Feline herpes virus ulcerative dermatitis is a rare feline skin disease caused by feline herpes virus 1. Feline herpesvirus 1 is known to cause mainly upper respiratory tract infection (Feline Viral Rhinotracheitis) and it is associated with many clinical symptoms which include: sneezing, nasal discharge, conjunctivitis, mouth ulcers and sometimes fever. In more severe cases breathing may be affected and secondary bacterial infection can develop.

This virus is highly contagious and spreads through direct contact between infected cats or via contaminated surfaces. Once the cat is infected, the virus remains in the body in a latent state, and presence of the virus has been demonstrated in the trigeminal ganglion. Following immunosuppression, the virus can start replicating again and lesions may occur.

In rare instances this virus can cause ulcerative dermatitis, particularly of the face, however, lesions have also been reported on the pinna and flank.

Clinically these lesions are characterised by vesicles, ulcers and crust formation which are variably pruritic. This is a non-specific clinical presentation, and differentials include: hypersensitivity to insect bites, eosinophilic granuloma complex lesions, pemphigus foliaceous, adverse drug reactions and even neoplasia.

Histopathology of this lesion can help distinguish between these entities. On histological examination these lesions are characterised by severe epidermal necrosis and ulceration which often extend into the wall of the underlying hair follicles. The inflammatory infiltrate is usually characterised by significant numbers of eosinophils, however, neutrophils may predominate on occasion. Intranuclear inclusion bodies, when identified, are diagnostic. These are usually observed in the areas of epithelial necrosis.

 

 

Figure 1: On low power the segmental epidermal necrosis and ulceration are evident (blue arrow).

 

 

Figure 2: The necrosis extends into the wall of hair follicles which are multifocally heavily infiltrated by mixed inflammation (blue circle area).

 

 

Figure 3: Large intranuclear inclusion bodies with associated chromatin margination are observed (blue arrow).

 

In the case presented here, inclusion bodies were readily identified, and the diagnosis was straightforward, however, herpes virus inclusion bodies may be difficult to detect or completely absent. In these cases, PCR testing may be useful. However, it is important to bear in mind that a previous vaccination with live vaccine may produce a false positive PCR result. This is due to virus latency and the fact that the PCR currently available in unable to distinguish between field and vaccination strains. Immunohistochemistry for feline herpes virus is also available commercially and it is considered the gold standard to confirm the diagnosis.

In summary, feline herpes virus 1 is a lifelong infection which is usually associated with mild disease, and it is largely prevented by vaccination. In rare cases infection becomes more severe and supportive care is required. Skin lesions associated with this infection are rare, however, they do occur, and, in these cases, histopathology is a very useful tool to identify it.

 

References

Persico, P., Roccabianca, P., Corona, A., Vercelli, A. and Cornegliani, L. (2011), Detection of feline herpes virus 1 via polymerase chain reaction and immunohistochemistry in cats with ulcerative facial dermatitis, eosinophilic granuloma complex reaction patterns and mosquito bite hypersensitivity. Veterinary Dermatology, 22: 521-527. https://doi.org/10.1111/j.1365-3164.2011.00984.x

Sánchez MD, Goldschmidt MH, Mauldin EA. Herpesvirus dermatitis in two cats without facial lesions. Vet Dermatol. 2012 Apr;23(2):171-3, e35. doi: 10.1111/j.1365-3164.2011.01031.

Porcellato I, Luciani L, Marenzoni ML, Santagostino SF, Sforna M, Mechelli L, Brachelente C. Feline herpesvirus ulcerative dermatitis: an atypical case? Vet Dermatol. 2018 Jun;29(3):258-e96. doi: 10.1111/vde.12537

Parzefall, Matiasek, Evidence of feline herpesvirus-1 DNA in the vestibular ganglion of domestic cats, The Veterinary Journal, Volume 184, Issue 3, 2010, Pages 371-372, ISSN 1090-0233, https://doi.org/10.1016/j.tvjl.2009.03.030.

 

By 0 Comments

Feline Ventral Abdominal Wall Angiosarcoma

Case Study: Feline Ventral Abdominal Wall Angiosarcoma

Clinical history

Simba, 9 year old male intact domestic shorthair cat, presented with firm rapidly growing large subcutaneous ulcerated mass on the inguinal area.  The ventral abdominal haired skin containing a portion of the inguinal mass and the inguinal lymph node are submitted for histopathology.

Histology

The dermis and the subcutis are markedly expanded by a moderately cellular neoplasm. Neoplastic cells are either forming anastomosing poorly-organised vascular spaces and channels, supported by a collagenous stroma, or are arranged in streams and sheets, closely packed, supported by a delicate fibrovascular stroma (Fig. 1 and 2). Neoplastic cells are elongated to spindle-shaped, with a prominent ovoid nucleus and small amphophilic nucleoli, and show moderate anisocytosis and anisokaryosis. Ten mitotic figures are observed in 2.37 mm2 – equivalent to 10 high power (x400) fields.

This neoplasm has metastasized to the inguinal lymph node (Fig. 3).

 

Figure 1: Haired skin. The dermis and the subcutis are effaced by a malignant vascular neoplasm, consistent with angiosarcoma (Haematoxylin and eosin stain, 5x).

 

 

Figure 2: Haired skin. Higher magnification of the angiosarcoma. Note the anastomosing poorly-organised vascular spaces (clear spaces, highlighted with asterisks), lined by a single layer of endothelium and  supported by a collagenous stroma (pink areas) (HE stain, 10x).

 

 

Figure 3: Inguinal lymph node. The nodal architecture is effaced by a metastatic angiosarcoma (HE stain, 10x).

 

Interpretation
Angiosarcoma, with nodal metastasis: ventral abdominal haired skin and inguinal lymph node.

Comments
Histology of the ventral abdominal haired skin submitted captures a malignant vascular neoplasm, consistent with angiosarcoma. In this particular case, this angiosarcoma has metastasised to the inguinal lymph node.

Angiosarcoma is a general term for a highly malignant neoplasm arising from endothelial cells of blood vessels (haemangiosarcoma) or lymphatic vessels (lymphangiosarcoma). If the neoplastic vascular channels are filled with blood, this would provide further evidence supporting a diagnosis of haemangiosarcoma. However, immunohistochemistry using endothelial cell markers (factor VIII and CD31) and  a lymphatic vessel marker (PROX-1) may be necessary to further characterise the neoplastic cells and determine whether the angiosarcoma represents a haemangiosarcoma or a lymphangiosarcoma. It should be noted, however, that it is currently unknown whether the different phenotypes affect treatment response or prognosis.

Angiosarcoma is rare in cats; however, the most commonly reported primary sites are cutaneous and visceral locations. Angiosarcomas in cats show a predilection for the subcutis of the caudal ventral abdominal wall, as observed in this case, and this condition is known as ‘feline ventral abdominal wall angiosarcoma’ (FVAA).

FVAA primarily affects middle-aged to older cats, with no distinct breed or gender predisposition.  Clinically, it manifests as a rapidly enlarging, firm to soft mass located in the ventral abdominal region. The mass may appear subcutaneous or involve deeper tissues, such as the abdominal musculature, and is prone to ulceration or spontaneous bleeding due to its vascular nature. Some patients  may present with lesions resembling bruising or inguinal hernia, which may not initially raise suspicion of a neoplastic process.

In addition to the mass, affected cats may present with non-specific clinical signs such as lethargy, anorexia, weight loss, and general malaise. If the neoplasm has metastasised or invaded adjacent structures, clinical signs can include respiratory distress (if pulmonary metastases are present), pale mucous membranes (due to internal haemorrhage), or abdominal distension.

Diagnosis of FVAA typically involves a thorough clinical examination, coupled with imaging studies such as ultrasound or radiography to evaluate the extent of the mass and to check for signs of metastasis. Fine-needle aspiration or core biopsy of the mass may provide initial cytological findings, often showing spindle-shaped or pleomorphic cells with abundant mitotic activity. However, cytology alone may not be definitive due to the poorly exfoliative nature of the cells, and histopathology is ultimately needed to diagnose this condition.

The prognosis for cats diagnosed with ventral abdominal wall angiosarcoma is generally guarded to poor, due to the highly aggressive and invasive nature of the tumour. Angiosarcomas have a marked propensity for local recurrence, even after seemingly complete surgical excision, and a high likelihood of metastasis. The lungs and liver are the most common sites of metastasis, but the tumour can also spread to other organs, including the spleen and kidneys.

Surgical resection is the primary treatment option, and wide surgical margins are essential to reduce the risk of recurrence. However, achieving complete excision can be difficult due to the tumour’s infiltrative growth pattern. Even with aggressive surgical intervention, recurrence rates are high, and the median survival time post-surgery is often limited to a few months. In cases where metastasis has already occurred at the time of diagnosis, survival time may be significantly shorter.

Overall, while early detection and aggressive surgical management may provide temporary control of the disease, the long-term outlook for cats with ventral abdominal wall angiosarcoma remains poor, and most cases have a guarded prognosis. Owners should be informed of the tumour’s aggressive behaviour and potential for rapid progression, and monitoring for recurrence is essential post-surgery.

 

Reference

Bellamy E, Larsen Moberg H, Suárez-Bonnet A, Palma SD, Murgia D, Pittaway R, Verganti S. Feline ventral abdominal wall angiosarcoma: haemangiosarcoma or lymphangiosarcoma? Clinical and pathological characteristics in nine cases. J Feline Med Surg. 2024 Jan;26(1):1098612X231216636. doi: 10.1177/1098612X231216636. PMID: 38227337; PMCID: PMC10949878.

 

By 0 Comments